Sign up to save your podcasts
Or
Share Clinical Perspective: New AEs from Newer ART
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Clinical Perspective: New AEs from Newer ART
Volume 4, Issue 8
While newer antiviral agents like darunavir and the integrase strand transfer inhibitor (INSTI) dolutegravir have shown great efficacy, recent postmarketing surveillance has identified important adverse effects not found in the clinical trial populations.
In this issue, Dr. Cody Chastain from the Division of Infectious Diseases at Vanderbilt University Medical Center discusses how these new findings can impact the clinical use of these new agents.
Take our post-test to claim CME credits.
To read a companion newsletter click here
The post Clinical Perspective: New AEs from Newer ART appeared first on DKBmed Radio.
Hosted on Acast. See acast.com/privacy for more information.
View all episodes
By eHIV Review
5
33 ratings
Volume 4, Issue 8
While newer antiviral agents like darunavir and the integrase strand transfer inhibitor (INSTI) dolutegravir have shown great efficacy, recent postmarketing surveillance has identified important adverse effects not found in the clinical trial populations.
In this issue, Dr. Cody Chastain from the Division of Infectious Diseases at Vanderbilt University Medical Center discusses how these new findings can impact the clinical use of these new agents.
Take our post-test to claim CME credits.
To read a companion newsletter click here
The post Clinical Perspective: New AEs from Newer ART appeared first on DKBmed Radio.
Hosted on Acast. See acast.com/privacy for more information.